Short Interest in Amarin Co. plc (NASDAQ:AMRN) Decreases By 12.1%

Amarin Co. plc (NASDAQ:AMRN) saw a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 15,840,000 shares, a decrease of 12.1% from the March 31st total of 18,020,000 shares. Based on an average trading volume of 1,680,000 shares, the short-interest ratio is presently 9.4 days.

Amarin Stock Performance

AMRN stock opened at $0.88 on Tuesday. Amarin has a 52-week low of $0.65 and a 52-week high of $1.49. The company’s 50 day simple moving average is $0.97 and its 200-day simple moving average is $0.94.

Amarin (NASDAQ:AMRN) last announced its earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.04. The company had revenue of $74.71 million for the quarter, compared to the consensus estimate of $72.46 million. Amarin had a negative net margin of 19.26% and a negative return on equity of 10.47%. On average, research analysts anticipate that Amarin will post -0.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Amarin in a report on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Amarin has a consensus rating of “Hold” and an average price target of $1.08.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AMRN. Newbridge Financial Services Group Inc. purchased a new position in Amarin during the 1st quarter valued at about $37,000. China Universal Asset Management Co. Ltd. grew its position in Amarin by 351.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 34,725 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in Amarin by 100.6% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 46,480 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 23,313 shares during the period. SVB Wealth LLC lifted its position in Amarin by 100.0% in the 4th quarter. SVB Wealth LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 30,000 shares in the last quarter. Finally, Gilliland Jeter Wealth Management LLC purchased a new stake in Amarin in the 4th quarter worth approximately $64,000. 22.25% of the stock is owned by institutional investors and hedge funds.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.